Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
P3-271: Clinical benefits of extended-release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial
Alzheimer's & Dementia · Vol. 9 Published January 1, 2013
More on these topics
Browse all publications →-
2019 · Neurology
The Effects of Memantine Added to Cholinesterase Inhibitors on NPI Behavioral Domains: Pooled Post Hoc Analysis of 3 Randomized Controlled Trials in Patients With Moderate to Severe AD (S9. 008)
-
2019 · Neurology
Efficacy of Memantine Added to Cholinesterase Inhibitors on SIB Higher-Order Cognitive Domains: Pooled Post Hoc Analysis of 2 Randomized Controlled Trials in Patients With Moderate to Severe AD (P4. 1-007)
-
2018 · Neurology
Memantine With Cholinesterase Inhibitors Maintains Improvements of Psychiatric Symptoms vs Cholinesterase Inhibitors Alone: Post Hoc Analyses From 3 Randomized, Double-blind, Placebo-controlled Studies in Patients With Alzheimer's Disease (P6. 177)
-
2018 · Neurology
Memantine ER With an AChEI Improves Individual SIB Scores Compared With AChEI Alone: Post Hoc Analyses From a Randomized, Double-blind, Placebo-controlled Study (P6. 173)